Dopaminski receptor D3

Izvor: Wikipedija
Prijeđi na navigaciju Prijeđi na pretragu
edit
Dopaminski receptor D3

Dopaminski D3 receptor sa etiklopridom (PDB 3PBL)
Dostupne strukture
3PBL
Identifikatori
SimboliDRD3; D3DR; ETM1; FET1
Vanjski IDOMIM126451 MGI94925 HomoloGene623 IUPHAR: D3 GeneCards: DRD3 Gene
Pregled RNK izražavanja
podaci
Ortolozi
VrstaČovekMiš
Entrez181413490
EnsemblENSG00000151577ENSMUSG00000022705
UniProtP35462P30728
RefSeq (mRNA)NM_000796.3NM_007877.1
RefSeq (protein)NP_000787.2NP_031903.1
Lokacija (UCSC)Chr 3:
113.85 - 113.92 Mb
Chr 16:
43.76 - 43.82 Mb
PubMed pretraga[1][2]

D3 dopaminski receptor je protein koji je kod ljudi kodiran DRD3 genom.[1][2]

D3 podtip dopaminskog receptora inhibira adenilil ciklazu putem inhibicije G proteina. Ovaj receptor je izražen u filogenetički starijim regionima mozga, što sugeriše da on ima ulogu u kognitivnim i emocionim funkcijama. On je meta za lekove kojima se tretira šizofrenija, addikcija, i Parkinsonova bolest [3] . Alternativno splajsovanje ovog gena proizvodi višestruke transkriptne varijante koje mogu da koriraju različite izoforme, mada neke varijante mogu da budu bez funkcije.[2]

D3 agonisti poput 7-OH-DPAT, pramipeksola, i rotigotina, pokazuju antidepresantne efekte u modelima na glodarima za depresiju.[4][5]

Ligandi[uredi | uredi kod]

Brojni neselektivni lekovi na recept se vezuju za D3 receptor. Među njima su neki od novijih dopaminskih agonista koji se koriste za lečenje Parkinsonove bolesti, npr. pramipeksol i ropinirol, koji se takođe vezuju za D2 i nemaju jaku selektivnost.

Agonisti[uredi | uredi kod]

  • 8-OH-PBZI (cis-8-Hidroksi-3-(n-propil)-1,2,3a,4,5,9b-heksahidro-1H-benz[e]indol)
  • PF-219,061 ((R)-3-(4-Propilmorfolin-2-il)fenol): >1000-puta funkcionalna (efikasnost) selektivnost u odnosu na D2[6]
  • jedinjenje R,R-16: 250x selektivnost vezivanja u odnosu na D2[7]
  • trans-N4-[4-(2,3-Dihlorofenil)-1-piperazinil]cikloheksil3-metoksibenzamid, pun agonist, > 200-puta selektivniji u odnosu na D4, D2, 5-HT1A, i α1-receptore[8]
  • (-)-7[2-(4-Fenilpiperazin-1-il)etil]propilamino5,6,7,8-tetrahidronaftalen-2-ol[9]
  • BP-897: parcijalni agonist[10]
  • FAUC 73
  • FAUC 460: parcijalni agonist, dobar afinitet i selektivnost[11]
  • FAUC 346: parcijalni agonist, podtip selektivan[12]
  • PD-128,907
  • jedinjenje 12: parcijalni agonist, Ki = 0.41nM, 800x selektivnost vezivanja u odnosu na D2[13]
  • piribedil[14]

Antagonisti[uredi | uredi kod]

  • N-(4-(4-(2,3-Dihloro- ili 2-metoksifenil)piperazin-1-il)butil)heterobiarilkarboksamidi[15]
  • FAUC 365, podtip selektivni antagonist[12]
  • jedinjenje 29[16]
  • Nafadotrid
  • NGB-2904[17]
  • SB-277011-A, selektivni D3 antagonist, 80x selektivniji u odnosu na D2 bez parcijalnog agonističkog dejstva. Koristi se u ispitivanjima za adikcije
  • Domperidon - D2 i D3 antagonist
Chemical structures of selective D3 receptor ligands.

Interakcije[uredi | uredi kod]

Dopaminski receptor D3 formira interakcije sa CLIC6[18] i EPB41L1.[19]

Reference[uredi | uredi kod]

  1. Le Coniat M, Sokoloff P, Hillion J, Martres MP, Giros B, Pilon C, Schwartz JC, Berger R (Oct 1991). „Chromosomal localization of the human D3 dopamine receptor gene”. Hum Genet 87 (5): 618–20. PMID 1916765. 
  2. 2,0 2,1 „Entrez Gene: DRD3 dopamine receptor D3”. 
  3. Joyce, JN; Millan, MJ (2007). „Dopamine D3 receptor agonists for protection and repair in Parkinson's disease.”. Current opinion in pharmacology 7 (1): 100–5. PMID 17174156. 
  4. Breuer ME, Groenink L, Oosting RS, et al. (August 2009). „Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats”. European Journal of Pharmacology 616 (1-3): 134–40. DOI:10.1016/j.ejphar.2009.06.029. PMID 19549514. 
  5. Bertaina-Anglade V, La Rochelle CD, Scheller DK (October 2006). „Antidepressant properties of rotigotine in experimental models of depression”. European Journal of Pharmacology 548 (1-3): 106–14. DOI:10.1016/j.ejphar.2006.07.022. PMID 16959244. 
  6. Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, Cook AS, Nichols CL, Phipps J, Sanderson VG, Verrier H, Wong S (2007). „Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route”. Bioorg. Med. Chem. Lett. 17 (24): 6691–6. DOI:10.1016/j.bmcl.2007.10.059. PMID 17976986. 
  7. Peglion JL, Poitevin C, La Cour CM, Dupuis D, Millan MJ (2009). „Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: Improvements of affinity and selectivity for D3 versus D2 receptors”. Bioorg. Med. Chem. Lett. 19 (8): 2133–8. DOI:10.1016/j.bmcl.2009.03.015. PMID 19324548. 
  8. Leopoldo M, Lacivita E, Colabufo NA, Berardi F, Perrone R (2006). „Synthesis and binding profile of constrained analogues of N-[4-(4-arylpiperazin-1-yl)butyl]-3-methoxybenzamides, a class of potent dopamine D3 receptor ligands”. J. Pharm. Pharmacol. 58 (2): 209–18. DOI:10.1211/jpp.58.2.0008. PMID 16451749. 
  9. Biswas S, Zhang S, Fernandez F, Ghosh B, Zhen J, Kuzhikandathil E, Reith ME, Dutta AK (2008). „Further structure-activity relationships study of hybrid 7[2-(4-phenylpiperazin-1-yl)ethyl]propylamino5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action”. J. Med. Chem. 51 (1): 101–17. DOI:10.1021/jm070860r. PMID 18072730. 
  10. Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR, Heidbreder C, Gaál J, Gardner EL (March 2008). „The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats”. Psychopharmacology 196 (4): 533–42. DOI:10.1007/s00213-007-0986-6. PMID 17985117. 
  11. Dörfler M, Tschammer N, Hamperl K, Hübner H, Gmeiner P (2008). „Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies”. J. Med. Chem. 51 (21): 6829–38. DOI:10.1021/jm800895v. PMID 18834111. 
  12. 12,0 12,1 Bettinetti L, Schlotter K, Hübner H, Gmeiner P (2002). „Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists”. J. Med. Chem. 45 (21): 4594–7. DOI:10.1021/jm025558r. PMID 12361386. 
  13. Chen J, Collins GT, Zhang J, et al (2008). „Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile”. J. Med. Chem. 51 (19): 5905–8. DOI:10.1021/jm800471h. PMC 2662387. PMID 18785726. 
  14. Cagnotto A, Parotti L, Mennini T (October 1996). „In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study”. Eur. J. Pharmacol. 313 (1-2): 63–7. DOI:10.1016/0014-2999(96)00503-1. PMID 8905329. 
  15. Newman AH, Grundt P, Cyriac G, et al (2009). „N-(4-(4-(2,3-Dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with Functionalized Linking Chains as High Affinity and Enantioselective D3 Receptor Antagonists ( parallel) ( perpendicular)”. J. Med. Chem. 52 (8): 2559. DOI:10.1021/jm900095y. PMC 2760932. PMID 19331412. 
  16. Grundt P, Carlson EE, Cao J, et al (2005). „Novel heterocyclic trans olefin analogues of N4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor”. J. Med. Chem. 48 (3): 839–48. DOI:10.1021/jm049465g. PMID 15689168. 
  17. Xi ZX, Gardner EL (2007). „Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction”. CNS Drug Reviews 13 (2): 240–59. DOI:10.1111/j.1527-3458.2007.00013.x. PMID 17627675. 
  18. Griffon, Nathalie; Jeanneteau Freddy, Prieur Fanny, Diaz Jorge, Sokoloff Pierre (September 2003). „CLIC6, a member of the intracellular chloride channel family, interacts with dopamine D(2)-like receptors”. Brain Res. Mol. Brain Res. (Netherlands) 117 (1): 47–57. DOI:10.1016/S0169-328X(03)00283-3. ISSN 0169-328X. PMID 14499480. 
  19. Binda, Alicia V; Kabbani Nadine, Lin Ridwan, Levenson Robert (September 2002). „D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N”. Mol. Pharmacol. (United States) 62 (3): 507–13. DOI:10.1124/mol.62.3.507. ISSN 0026-895X. PMID 12181426. 

Literatura[uredi | uredi kod]

Vidi još[uredi | uredi kod]

Spoljašnje veze[uredi | uredi kod]